257876-32-7

Basic information

• Product Name: (S)-2-(tert-butyldiphenylsilyloxymethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indole
• Synonyms: (S)-2-(tert-butyldiphenylsilyloxymethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indole
• CAS NO: 257876-32-7
• Molecular Weight: 425.646
• Mol File: 257876-32-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-2-(tert-butyldiphenylsilyloxymethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indole(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(tert-butyldiphenylsilyloxymethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indole(257876-32-7)
• EPA Substance Registry System: (S)-2-(tert-butyldiphenylsilyloxymethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indole(257876-32-7)

Safety Data

• Hazardous Substances Data: 257876-32-7(Hazardous Substances Data)

Upstream product

• 23193-22-8 indol-2-ylmethyl-malonic acid diethyl ester 
• 65828-72-0 diethyl (1H-indol-2-ylmethylene)malonate 
• 19005-93-7 1H-indol-2-ylcarboxaldehyde 
• 257876-19-0 acetic acid 3-(tert-butyl-diphenyl-silanyloxy)-2-(1H-indol-2-ylmethyl)-propyl ester 
• 257876-20-3 (S)-2-(tert-butyldiphenylsilyloxymethyl)-3-(1H-indol-2-yl)propan-1-ol 
• 257876-18-9 (R)-3-hydroxy-2-(1H-indol-2-ylmethyl)propyl acetate 
• 257876-17-8 2-(1H-indol-2-ylmethyl)propane-1,3-diol 

Downstream Products

• 908338-20-5 (R)-3-[2-(aminomethyl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-9-yl]-4-(phenylamino)-1H-pyrrole-2,5-dione 
• 257880-21-0 3-(2-hydroxymethyl-2,3-dihydro-1H-3a-aza-cyclopenta[a]inden-8-yl)-4-phenylamino-pyrrole-2,5-dione 
• 257876-37-2 methanesulfonic acid 8-(2,5-dioxo-4-phenylamino-2,5-dihydro-1H-pyrrol-3-yl)-2,3-dihydro-1H-3a-aza-cyclopenta[a]inden-2-ylmethyl ester 

Relevant articles and documents

Synthesis, SAR studies, and pharmacological evaluation of 3-anilino-4-(3-indolyl) maleimides with conformationally restricted structure as orally bioavailable PKCβ-selective inhibitors

Conformationally restricted 3-anilino-4-(3-indolyl)maleimide derivatives were designed and synthesized aiming at discovery of novel protein kinase Cβ (PKCβ)-selective inhibitors possessing oral bioavailability. Among them, compounds having a fused five-me